Fitch Rating upgrades rating of various bank facilities of Nectar Lifesciences

23 May 2011 Evaluate

Fitch Rating has upgraded Nectar Lifesciences’ long-term bank facilities rating to ‘A-(ind)’ from ‘BBB+ (ind)’ with stable outlook. The rating agency has also upgraded rating of Rs 490 crore long-term loans facilities of the company to ‘A-(ind)’ from ‘BBB+(ind)’, upgraded Rs 350 crore fund-based limits of the company to ‘A-(ind)/F1(ind)’ from ‘BBB+(ind)/’F2+(ind)’ and upgraded the company’s Rs 280 crore non-fund based limits to ‘F1(ind)’ from ‘F2+(ind)’.

The upgrades reflect strong revenue growth in the company’s pharmaceutical segment, coupled with an improvement in overall profitability margins. The upgrades also reflect an Rs 250 crore equity infusion through private equity investment and global depository receipts in March 2010 as well as an improvement in the company's credit profile and its comfortable liquidity profile over FYE10-FYE11.

Nectar Lifesciences is a $200 million pharmaceutical organization. The company offers a range of Cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms.

Nectar Lifesciences Share Price

39.11 1.76 (4.71%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.